Castle Biosciences, Inc. CSTL
$35.17
$1.735.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -105.10% | -153.15% | -232.41% | -301.42% | -205.45% |
| Total Depreciation and Amortization | -110.61% | -33.09% | 29.22% | 68.45% | 224.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 53.74% | -50.84% | 21.19% | 3.62% | -9.85% |
| Change in Net Operating Assets | 179.52% | 193.09% | 196.29% | 119.13% | 24.19% |
| Cash from Operations | -31.77% | -26.51% | -0.80% | 4.56% | 53.30% |
| Capital Expenditure | -54.30% | -82.89% | -27.17% | -48.27% | -35.48% |
| Sale of Property, Plant, and Equipment | 15.63% | 95.45% | 150.00% | 235.71% | 166.67% |
| Cash Acquisitions | 99.99% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.53% | 95.45% | 74.05% | 78.63% | 65.19% |
| Cash from Investing | 14.21% | -20.56% | -20.40% | 0.24% | -2.27% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | 0.93% | -29.89% | -18.56% | -6.54% | 10.08% |
| Issuance of Common Stock | 19.77% | 8.09% | -7.52% | -40.07% | 60.35% |
| Repurchase of Common Stock | -47.94% | -45.70% | -33.04% | -66.74% | -100.50% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -626.32% | -- | -- | -- | -- |
| Cash from Financing | -90.48% | -72.33% | -213.37% | -194.27% | -180.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -502.49% | -484.64% | -114.28% | -351.69% | 67.59% |